These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31267313)

  • 1. Inhibition of Ubc9-Induced CRMP2 SUMOylation Disrupts Glioblastoma Cell Proliferation.
    Wang L; Ji S
    J Mol Neurosci; 2019 Nov; 69(3):391-398. PubMed ID: 31267313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.
    Moutal A; Villa LS; Yeon SK; Householder KT; Park KD; Sirianni RW; Khanna R
    Mol Neurobiol; 2018 May; 55(5):4403-4416. PubMed ID: 28660485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking.
    Dustrude ET; Wilson SM; Ju W; Xiao Y; Khanna R
    J Biol Chem; 2013 Aug; 288(34):24316-31. PubMed ID: 23836888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.
    François-Moutal L; Dustrude ET; Wang Y; Brustovetsky T; Dorame A; Ju W; Moutal A; Perez-Miller S; Brustovetsky N; Gokhale V; Khanna M; Khanna R
    Pain; 2018 Oct; 159(10):2115-2127. PubMed ID: 29847471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels.
    François-Moutal L; Scott DD; Perez-Miller S; Gokhale V; Khanna M; Khanna R
    Channels (Austin); 2018; 12(1):219-227. PubMed ID: 30081699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SUMOylation in Glioblastoma: A Novel Therapeutic Target.
    Fox BM; Janssen A; Estevez-Ordonez D; Gessler F; Vicario N; Chagoya G; Elsayed G; Sotoudeh H; Stetler W; Friedman GK; Bernstock JD
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30991648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.
    Ju W; Li Q; Wilson SM; Brittain JM; Meroueh L; Khanna R
    Channels (Austin); 2013; 7(3):153-9. PubMed ID: 23510938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-SUMOylated CRMP2 decreases Na
    Gomez K; Ran D; Madura CL; Moutal A; Khanna R
    Mol Brain; 2021 Jan; 14(1):20. PubMed ID: 33478555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the impact of SUMOylation at K298 site of heat shock factor 1 on glioblastoma malignant progression.
    Li X; Wang Z; Gao B; Dai K; Wu J; Shen K; Li G; Niu X; Wu X; Li L; Shen H; Li H; Yu Z; Wang Z; Chen G
    Neoplasia; 2024 Nov; 57():101055. PubMed ID: 39260131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function.
    Dustrude ET; Perez-Miller S; François-Moutal L; Moutal A; Khanna M; Khanna R
    Channels (Austin); 2017 Jul; 11(4):316-328. PubMed ID: 28277940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal CRMP2-Ubc9 inhibitor regulates Na V 1.7 to alleviate trigeminal neuropathic pain.
    Loya-Lopez SI; Allen HN; Duran P; Calderon-Rivera A; Gomez K; Kumar U; Shields R; Zeng R; Dwivedi A; Saurabh S; Korczeniewska OA; Khanna R
    Pain; 2024 Mar; 165(3):573-588. PubMed ID: 37751532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain.
    Moutal A; Cai S; Yu J; Stratton HJ; Chefdeville A; Gomez K; Ran D; Madura CL; Boinon L; Soto M; Zhou Y; Shan Z; Chew LA; Rodgers KE; Khanna R
    Pain; 2020 Nov; 161(11):2629-2651. PubMed ID: 32569093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
    J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mir-758-5p Suppresses Glioblastoma Proliferation, Migration and Invasion by Targeting ZBTB20.
    Liu J; Jiang J; Hui X; Wang W; Fang D; Ding L
    Cell Physiol Biochem; 2018; 48(5):2074-2083. PubMed ID: 30099442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hierarchical CRMP2 posttranslational modifications control NaV1.7 function.
    Dustrude ET; Moutal A; Yang X; Wang Y; Khanna M; Khanna R
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8443-E8452. PubMed ID: 27940916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1.
    Lin CH; Liu SY; Lee EH
    Oncogene; 2016 Feb; 35(5):595-607. PubMed ID: 25867063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBC9 stabilizes PFKFB3 to promote aerobic glycolysis and proliferation of glioblastoma cells.
    Meng Z; Bian X; Ma L; Zhang G; Ma Q; Xu Q; Liu J; Wang R; Lun J; Lin Q; Zhao G; Jiang H; Qiu W; Fang J; Lu Z
    Int J Biochem Cell Biol; 2023 Dec; 165():106491. PubMed ID: 38149579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Wnt5a in the proliferation of human glioblastoma cells.
    Yu JM; Jun ES; Jung JS; Suh SY; Han JY; Kim JY; Kim KW; Jung JS
    Cancer Lett; 2007 Nov; 257(2):172-81. PubMed ID: 17709179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9.
    Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
    J Chem Inf Model; 2014 Oct; 54(10):2784-93. PubMed ID: 25191977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of CRMP2 Post-Translational Modifications Drive Its Pathological Functions.
    Moutal A; White KA; Chefdeville A; Laufmann RN; Vitiello PF; Feinstein D; Weimer JM; Khanna R
    Mol Neurobiol; 2019 Oct; 56(10):6736-6755. PubMed ID: 30915713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.